Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer

Beatrice Wichert, Karin Milde-Langosch, Vladimir Galatenko, Barbara Schmalfeldt, Leticia Oliveira-Ferrer

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Aberrant sialylation of glycoproteins has been detected in many tumors, and upregulation of the beta-galactosamide alpha-2,6-sialyltransferase 1 (ST6GAL1) has been implicated with tumor aggressiveness and chemoresistance in experimental models. In our present study, we aimed to study the prognostic or predictive role of ST6GAL1 in ovarian carcinoma, using two independent ovarian cancer cohorts. ST6GAL1 mRNA levels were retrieved from a publicly available database (n = 517), and ST6GAL1 protein levels were analyzed by western blot analysis in a cohort of 204 ovarian tumor samples. The results were correlated with clinical and histological tumor parameters and follow-up information. High ST6GAL1 mRNA levels significantly correlated with lymphovascular invasion and shorter survival, whereas high ST6GAL1 protein expression was associated with advanced stage, distant metastasis and shorter recurrence-free intervals. In both cohorts the prognostic role was most pronounced in tumors without macroscopically visible residual tumor after surgery. In these cases, ST6GAL1 expression levels might help to identify cases with a higher risk of chemoresistance and metastatic relapse that might require an adapted therapeutic regime.

Original languageEnglish
Pages (from-to)898-903
Number of pages6
Issue number11
StatePublished - 1 Nov 2018
Externally publishedYes


  • Ovarian cancer
  • Prognosis
  • ST6GAL1
  • Sialyltransferase


Dive into the research topics of 'Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer'. Together they form a unique fingerprint.

Cite this